WCI

RI Related News

비회원이 작성한 글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.

List Next Prev
게시글 내용
NorthStar Medical Radioisotopes and IBA sign contract for RHODOTRON® electron beam accelerator for commercial Production of Therapeutic Radioisotope actinium-225 (Ac-225)
2021/12/01

NorthStar Medical Radioisotopes, LLC (NorthStar), engaged in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), a major manufacturer in particle accelerator technology, have announced a new contract in which NorthStar will purchase a third Rhodotron® TT300 HE electron beam accelerator from IBA.

 

The accelerator will be exclusively used for the production of no-carrier added (n.c.a.) actinium-225 (Ac-225), an important therapeutic radioisotope that is in highly limited supply and for which no commercial-scale production technology currently exists. NorthStar previously purchased two Rhodotron® accelerators from IBA for its newly completed molybdenum-99 (Mo-99) production facility.

 

The final stage of facility design is underway for NorthStars state-of-the-art Therapeutic Radioisotope production facility, which will be exclusively dedicated to Ac-225 production, with construction scheduled to begin in early 2022. Initial production of Ac-225 is planned for late 2023, and a Drug Master File is expected to be submitted to the FDA in 2024. NorthStars proprietary process for the production of Ac-225 will use IBAs Rhodotron® to enable commercial-scale n.c.a. Ac-225 production that is free of long-life radioactive byproducts associated with other production methods.

 

To read more please visit:

NorthStar Medical Radioiosotopes and IBA sign contract for RHODOTRON® electron beam accelerator for commercial Production of Therapeutic Radioisotope actinium-225 (Ac-225)

Source: NorthStar